Contact – +1-276-477-5910
 Email – [email protected]

Home >>

Healthcare

>>

North America Human Insulin Market


North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Report code: SDMRHE847782 | Industry: Healthcare | Published On: 1/18/2020


North America human insulin market is expected to reach $23.52 billion by 2025, growing by 7.36% annually over the next years.
Highlighted with 27 tables and 52 figures, this 105-page report “North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify North America human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.
Based on product type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Human Insulin Drugs
• Human Insulin Delivery Devices
Based on product, the North America Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)
• Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)
Based on product, the North America Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Syringes
• Pens (further segmented into Disposable, Reusable, Pen needles)
• Pumps
• Others
Based on application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes and Prediabetes
Based on distribution channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America human insulin market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players:
Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt
(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1  Introduction 5
1.1  Industry  Definition  and  Research  Scope 5
1.1.1  Industry  Definition 5
1.1.2  Research  Scope 6
1.2  Research  Methodology 8
1.2.1  Overview  of  Market  Research  Methodology 8
1.2.2  Market  Assumption 9
1.2.3  Secondary  Data 9
1.2.4  Primary  Data 9
1.2.5  Data  Filtration  and  Model  Design 10
1.2.6  Market  Size/Share  Estimation 11
1.2.7  Research  Limitations 12
1.3  Executive  Summary 13
2  Market  Overview  and  Dynamics 15
2.1  Market  Size  and  Forecast 15
2.2  Major  Growth  Drivers 16
2.3  Market  Restraints  and  Challenges 19
2.4  Emerging  Opportunities  and  Market  Trends 22
2.5  Porter’s  Fiver  Forces  Analysis 25
3  Segmentation  of  North  America  Market  by  Product  Type 29
3.1  Market  Overview  by  Product  Type 29
3.2  Human  Insulin  Drugs 31
3.3  Human  Insulin  Delivery  Devices 32
4  Segmentation  of  North  America  Human  Insulin  Drugs  Market  by  Drug  Product 33
4.1  Market  Overview  by  Drug  Product 33
4.2  Modern  Human  Insulin 35
4.2.1  Modern  Human  Insulin  by  Type 37
4.2.2  Modern  Human  Insulin  by  Brand 41
4.3  Traditional  Human  Insulin 48
4.3.1  Traditional  Human  Insulin  by  Type 50
4.3.2  Traditional  Human  Insulin  by  Brand 53
5  Segmentation  of  North  America  Human  Insulin  Delivery  Devices  Market  by  Device  Product 56
5.1  Market  Overview  by  Product 56
5.2  Syringes 58
5.3  Pens 59
5.4  Pumps 60
5.5  Other  Devices 62
6  Segmentation  of  North  America  Market  by  Application 63
6.1  Market  Overview  by  Application 63
6.2  Type  1  Diabetes 65
6.3  Type  2  Diabetes 66
6.4  Gestational  Diabetes  and  Prediabetes 67
7  Segmentation  of  North  America  Market  by  Distribution  Channel 68
7.1  Market  Overview  by  Distribution  Channel 68
7.2  Hospital  Pharmacies 70
7.3  Retail  Pharmacies 71
7.4  Online  Pharmacies 72
8  North  America  Market  2019-2026  by  Country 73
8.1  Overview  of  North  America  Market 73
8.2  U.S.  Market 76
8.3  Canadian  Market 80
9  Competitive  Landscape 82
9.1  Overview  of  Key  Vendors 82
9.2  New  Product  Launch,  Partnership,  Investment,  and  M&A 86
9.3  Company  Profiles 88
Astra  Zeneca  PLC 88
Biocon 90
Eli  Lilly 91
Exir 92
Julphar 93
Novo  Nordisk  AS 94
Pfizer 95
Sanofi  Aventis 96
Sedico 97
Wockhardt 98
10  Investing  in  North  America  Market:  Risk  Assessment  and  Management 99
10.1  Risk  Evaluation  of  North  America  Market 99
10.2  Critical  Success  Factors  (CSFs) 102
Related  Reports  and  Products 105
Table 1. Snapshot of North America Human Insulin Market, 2019-2026 14
Table 2. Main Product Trends and Market Opportunities in North America Human Insulin Market 22
Table 3. North America Human Insulin Market by Product Type, 2019-2026, $ mn 29
Table 4. North America Human Insulin Drugs Market by Product, 2019-2026, $ mn 33
Table 5. North America Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, $ mn 36
Table 6. North America Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, $ mn 36
Table 7. North America Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, $ mn 49
Table 8. North America Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, $ mn 49
Table 9. North America Human Insulin Delivery Devices Market by Product, 2019-2026, $ mn 56
Table 10. North America Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, $ mn 59
Table 11. North America Human Insulin Market by Application, 2019-2026, $ mn 63
Table 12. North America Human Insulin Market by Distribution Channel, 2019-2026, $ mn 68
Table 13. North America Human Insulin Market by Country, 2019-2026, $ mn 74
Table 14. U.S. Human Insulin Market by Product Type, 2019-2026, $ mn 78
Table 15. U.S. Human Insulin Market by Application, 2019-2026, $ mn 78
Table 16. U.S. Human Insulin Market by Distribution Channel, 2019-2026, $ mn 78
Table 17. Canada Human Insulin Market by Product Type, 2019-2026, $ mn 81
Table 18. Canada Human Insulin Market by Application, 2019-2026, $ mn 81
Table 19. Canada Human Insulin Market by Distribution Channel, 2019-2026, $ mn 81
Table 20. North America Human Insulin Market by Key Vendor, 2019, $ mn 84
Table 21. Astra Zeneca PLC: Company Snapshot 88
Table 22. Astra Zeneca PLC: Business Segmentation 88
Table 23. Astra Zeneca PLC: Product Portfolio 89
Table 24. Astra Zeneca PLC: Revenue, 2016-2018, $ mn 89
Table 25. Astra Zeneca PLC: Recent Developments 89
Table 26. Risk Evaluation for Investing in North America Market, 2019-2026 100
Table 27. Critical Success Factors and Key Takeaways 103
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT